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Background
There is an emerging consensus that cGMP has functions
in the intestinal epithelium that go beyond the regulation
of secretion. Observations in mice that are deficient in
cGMP signaling components have revealed an important
role in epithelial homeostasis, and such animals exhibit
defective barrier function and increased susceptibility to
intestinal tumorigenesis. Despite recent clinical success
with the GCC-agonist Linzess® (linaclotide) in treating
constipation, few studies have examined the effect of
these agents in colitis or colon cancer models. In addi-
tion, a paucity of work focusing on the effects of cGMP
elevating agents in wild type mice have left signaling
downstream of cGMP and the therapeutic mechanisms
poorly understood.
Results
Our laboratory has reported that clinically relevant phos-
phodiesterase 5 (PDE5) inhibitors can produce sustained
increases in cGMP levels in the intestinal epithelium. In
support of previous work with knockout mice, we further
demonstrated that PDE5 inhibitors promote the differen-
tiation of colonic secretory cells, and alter homeostasis by
suppressing both apoptosis in the luminal epithelium and
proliferation in the crypts. These effects of increased
cGMP in the colon mucosa led to the suppression of coli-
tis and tumorigenesis in preclinical disease models. The
cGMP-dependent signaling pathways identified as likely
contributors to the therapeutic effects of PDE5 inhibitors
in the gut include PKG2-dependent activation of DUSP10
and FoxO. These pathways are capable of increasing
epithelial resilience to redox stress and suppressing tumor
proliferation. Preliminary results indicate that these path-
ways might also be activated by cGMP in the human
colon mucosa, which highlights the potential utility of
PDE5 inhibitors for the prevention and treatment of colitis
and colon cancer.
Conclusion
Signaling through cGMP has profound physiological
effects in the gut mucosa that can be exploited using
GCC-agonists and PDE5 inhibitors. While our under-
standing of the underlying mechanisms is relatively poor,
these agents have significant therapeutic potential for the
treatment of gastrointestinal diseases.
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